2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP

Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 2,919,110 shares of the company’s stock, valued at approximately $64,308,000. Wellington Management Group LLP owned 2.25% of Kailera Therapeutics as of its most recent filing with the SEC.

Kailera Therapeutics Stock Down 3.4%

NASDAQ KLRA opened at $15.85 on Thursday. The firm has a 50 day simple moving average of $18.73. The firm has a market capitalization of $2.05 billion and a P/E ratio of -0.00. Kailera Therapeutics, Inc. has a 12-month low of $15.15 and a 12-month high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA) last announced its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, sell-side analysts predict that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KLRA. TD Cowen initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price objective for the company. Weiss Ratings began coverage on shares of Kailera Therapeutics in a research note on Friday, August 14th. They issued a “sell (d)” rating for the company. William Blair initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating for the company. Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target on the stock. Finally, Leerink Partners assumed coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kailera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $42.75.

Kailera Therapeutics Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.